权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Proliferative activities of non-palpable breast cancer detected by mammography

乳腺X线摄影检测不可触及乳腺癌的增殖活性

基本信息

批准号：
05671031
负责人：
FUKUDA Mamoru
金额：
$ 1.22万
依托单位：
St.Marianna University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

项目摘要

Proliferative activities of non-palpable breast cancer detected by mammography were evaluated in order to rationalize surgical treatment for them. Overexpression of p34^<cdc2>, c-erbB-2 and p53 have been studied. Overexpression of p34^<cdc2> was observed in 14/58 (24.1%) of the palpable breast cancers by western blotting. In contrast, overexpression of p34^<cdc2> was not observed in 12 normal breast tissues (0%). Therefore it was considered that overexpression of p34^<cdc2> indicated proliferative activities of breast cancerous tissues. Subsequently immunostaining for p34^<cdc2> overexpression was carried out using paraffin-embedded sections. Proportions of positive p34^<cdc2> staining cells among observed cells were assessed in five x400 fields. Ratios of positive p34^<cdc2> staining cells were more than 2 % in 1 of 6 (16.7%) fibrocystic diseases, 16 of 16 (100%) non-palpable breast cancers and 8 of 8 (100%) palpable breast cancers. Ratios of positive p34^<cdc2> staining cells were more than 4 % in 1 of 6 (16.7%) fibrocystic diseases, 6 of 16 (37.5%) non-palable breast cancers and 7 of 8 (87.5%) palpable breast cancers. In none of 4 (0%) fibrocystic diseases the c-erbB-2 immunostaining were positive. In contrast, c-erbB-2 immunostainings were positive in 8 of 16 (50%) non-palpable breast cancers. The p53 immunostainings were positive in one of 4 (25%) fibrocystic diseases and 3 of 16 (20%) non-palpable breast cancers. In conclusion, it is likely that overexpression of p34^<cdc2> reflects high proliferative activities of breast cancer. Higher ratios of positive p34^<cdc2> staining cells and stronger intensity of c-erbB-2 immunostaining in non-palpable breast cancer compared with fibrocystic disease indicate that non-palpable breast cancer detected by mammography is candidate for surgical therapy.

本文对乳腺钼靶X线检查发现的乳腺癌的放射性进行了评价，以指导手术治疗。研究了p34、<cdc2>c-erbB-2和p53的过表达。免疫<cdc2>印迹法检测58例可触及乳腺癌中p34 ~+表达阳性率为24.1%（14/58）。相反，<cdc2>在12例正常乳腺组织中未观察到p34 α过表达（0%）。因此，认为p34 α的过表达<cdc2>指示乳腺癌组织的增殖活性。随后，<cdc2>使用石蜡包埋切片进行p34 α过表达的免疫染色。在<cdc2>5个x400视野中评估观察到的细胞中阳性p34+染色细胞的比例。6<cdc2>例乳腺纤维囊性病变中1例（16.7%）p34 ~+染色阳性细胞率> 2%，16例乳腺癌中16例（100%），8例乳腺癌中8例（100%）。6<cdc2>例纤维囊性病变中1例（16.7%）p34 ~+染色阳性细胞率> 4%，16例触诊阴性乳腺癌中6例（37.5%）p34 ~+染色阳性细胞率> 4%，8例触诊阳性乳腺癌中7例（87.5%）阳性细胞率> 4%。4例纤维囊性病变c-erbB-2免疫组化均为阴性。与此相反，c-erbB-2免疫染色阳性的16个（50%）非触诊乳腺癌中的8个。4例乳腺纤维囊性病变中1例（25%）p53阳性，16例乳腺癌中3例（20%）p53阳性。总之，p34 α的过表达可能<cdc2>反映了乳腺癌的高增殖活性。与<cdc2>纤维囊性疾病相比，不可触及的乳腺癌中p34 ~+染色细胞的阳性比例更高，c-erbB-2免疫染色强度更强，这表明通过乳房X光检查检测到的不可触及的乳腺癌是手术治疗的候选者。